GCM
IBB icon

Glaxis Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Glaxis Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,000
Closed -$1.1M – 46
2024
Q2 		$1.1M Buy
+8,000
New +$1.07M 1.89% 16

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Glaxis Capital Management's IBB Position: Q3 2024 in Review

Glaxis Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2024, closing a stake of 8,000 shares — an estimated $1.1M sold.

Glaxis Capital Management first reported a position in IBB in Q2 2024 and held it in 1 quarter. The position peaked at $1.1M in Q2 2024. 893 funds tracked by Wall St. Rank hold IBB as of Q3 2024.

  • Glaxis Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2024 after selling out during the quarter.
  • Glaxis Capital Management sold 8,000 iShares Biotechnology ETF shares in Q3 2024, an estimated $1.1M.
  • Glaxis Capital Management first reported a position in iShares Biotechnology ETF in Q2 2024 and held it in 1 quarter.
  • Glaxis Capital Management's iShares Biotechnology ETF position peaked at $1.1M in Q2 2024.
  • 893 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2024.

Based on Glaxis Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.